Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance

Automated insulin delivery systems, utilizing a control algorithm to dose insulin based upon subcutaneous continuous glucose sensor values and insulin pump therapy, will soon be available for commercial use. The objective of this study was to determine the preliminary safety and efficacy of initialization parameters with the Medtronic hybrid closed‐loop controller by comparing percentage of time in range, 70–180 mg/dL (3.9–10 mmol/L), mean glucose values, as well as percentage of time above and below target range between sensor‐augmented pump therapy and hybrid closed‐loop, in adults and adolescents with type 1 diabetes.

[1]  D. B. Keenan,et al.  The Use of an Automated, Portable Glucose Control System for Overnight Glucose Control in Adolescents and Young Adults With Type 1 Diabetes , 2012, Diabetes Care.

[2]  Effectiveness of early intensive therapy on b-cell preservation in type 1 diabetes , 2015 .

[3]  Eyal Dassau,et al.  Annals of the New York Academy of Sciences the Artificial Pancreas: Current Status and Future Prospects in the Management of Diabetes , 2022 .

[4]  Janet M. Allen,et al.  Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies , 2011, BMJ : British Medical Journal.

[5]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[6]  Stuart A Weinzimer,et al.  Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study , 2012, Journal of diabetes science and technology.

[7]  Bruce Buckingham,et al.  Glucose control in pediatric intensive care unit patients using an insulin-glucose algorithm. , 2007, Diabetes technology & therapeutics.

[8]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[9]  Roman Hovorka,et al.  Bringing closed-loop home: recent advances in closed-loop insulin delivery , 2014, Current opinion in endocrinology, diabetes, and obesity.

[10]  Bruce A. Buckingham,et al.  In‐home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes , 2017, Pediatric diabetes.

[11]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[12]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[13]  F. Pigula,et al.  Tight glycemic control versus standard care after pediatric cardiac surgery. , 2012, The New England journal of medicine.

[14]  Roman Hovorka,et al.  Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol , 2014, BMJ Open.

[15]  Marc D. Breton,et al.  Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas , 2014, Diabetes Care.

[16]  Roman Hovorka,et al.  Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.

[17]  Ahmad Haidar,et al.  Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes , 2013, Diabetes Care.

[18]  Roman Hovorka,et al.  Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study , 2014, Diabetes Care.

[19]  R. Beck,et al.  Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines , 2013, Diabetes Care.

[20]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[21]  Anirban Roy,et al.  Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes , 2012, Diabetes Care.

[22]  Ahmad Haidar,et al.  Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. , 2015, The lancet. Diabetes & endocrinology.

[23]  Benyamin Grosman,et al.  Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp , 2015, Diabetes Care.

[24]  Janet M. Allen,et al.  Day and Night Closed-Loop Control in Adults With Type 1 Diabetes , 2013, Diabetes Care.